| Literature DB >> 32487118 |
Monika Kamkuemah1, Blessings Gausi2, Tolu Oni2,3.
Abstract
BACKGROUND: Epidemiological transition in high HIV-burden settings is resulting in a rise in HIV/NCD multimorbidity. The majority of NCD risk behaviours start during adolescence, making this an important target group for NCD prevention and multimorbidity prevention in adolescents with a chronic condition such as HIV. However, there is data paucity on NCD risk and prevention in adolescents with HIV in high HIV-burden settings. The aim of this study was to investigate the extent to which NCD comorbidity (prevention, diagnosis, and management) is incorporated within existing adolescent HIV primary healthcare services in Cape Town, South Africa.Entities:
Keywords: Adolescents; HIV; Multimorbidity; Non-communicable Disease; Youth
Year: 2020 PMID: 32487118 PMCID: PMC7268240 DOI: 10.1186/s12889-020-08921-0
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Study population and sampling methodology across sub-districts
Demographic and HIV-related characteristics of 491 participants aged 10–24 years receiving ART across Cape Town, November 2018–March 2019
| Characteristic | Median (IQR) or n (%)b | ||
|---|---|---|---|
| Age at folder review (years) | 20 (14–23) | ||
| Male | 127 (26%) | ||
| HIV management | Age at ART initiation (years) | 473 (96%) | 18 (6–21) |
| Duration on ART (years) | 471 (96%) | 3.1 (1.1–8.9) | |
| CD4 count (cells/mm3) | 395 (80%) | 489 (355 --690) | |
| Viral suppression (< 20 copies/ml) | 369 (75%) | 256 (69%) | |
| Current ART regimenc | 84 (17%) | ||
| TDF FTC EFV | 298 (61%) | ||
| 39 (8%) | |||
| AZT 3TC LPV/r | 29 (6%) | ||
| Other regimens | 41 (8%) | ||
| HIV opportunistic infections | 28 (6%) | ||
| Herpes zoster (shingles) | 11 (39%) | ||
| Pruritic papular eruption | 8 (29%) | ||
| Oral thrush | 2 (7%) | ||
| Oral candida | 2 (7%) | ||
| Oral hairy leucoplakia | 1 (3.6%) | ||
| Oesophageal candidiasis | 1 (3.6%) | ||
| 1 (3.6%) | |||
| HIV Encephalopathy | 1 (3.6%) | ||
| Cytomegalovirus disease | 1 (3.6%) | ||
| ART-related conditionsd | 8 (2%) | ||
| AZT-neutropenia | 1 (13%) | ||
| D4T-lipodystrophy, lipoatrophy | 7 (87%) | ||
aDenominator = 491, unless otherwise indicated in this column; bPercentages may not total 100 due to rounding; cCurrent ART regimens: ABC Abacavir, 3TC lamivudine, EFV efavirenz, TDF tenofovir, FTC emtricitabine, LPV/r lopinavir/ritonavir; dART-related conditions: AZT zidovudine, D4T stavudine
NCD comorbidity, general medical information and health promotion interventions documented in folders of 491 participants aged 10–24 years receiving ART across Cape Town, November 2018–March 2019
| Characteristic | n (%)b | ||
|---|---|---|---|
| 268 (55%) | |||
| NCD diagnosis | 30 (11%) | ||
| Depression, anxiety or other mental health condition | 11 (37%) | ||
| Bronchitis, lung disease, asthma or other chronic respiratory diseasec | 18 (60%) | ||
| Cancer | 1 (3%) | ||
| NCD treatment | 4 (1%) | ||
| Asthma treatment | 1 (25%) | ||
| High Blood Pressure treatment | 1 (25%) | ||
| Antipsychotic medication | 1 (25%) | ||
| High cholesterol/ triglycerides | 1 (25%) | ||
| NCD risk factors | 305 (62%) | ||
| Smoking: current smoker or history of smoking | 11 (4%) | ||
| Alcohol, drugs or other substance abuse | 9 (3%) | ||
| Body Mass Index (BMI) kg/m2 | 305 (62%) | ||
| Underweight: BMI < 18.5 | 30 (10%) | ||
| Normal weight: BMI 18.5–25 | 129 (42%) | ||
| Overweight: BMI 25–30 | 80 (26%) | ||
| Obese: BMI ≥30 | 66 (22%) | ||
| Blood Pressure mmHgd | 289 (59%) | ||
| Normal: SBP < 130 and DBP < 85 | 210 (73%) | ||
| High normal: SBP 130–139/DBP 85–89 | 41 (14%) | ||
| Mild hypertension: SBP 140–159/DBP 90–99 | 35 (12%) | ||
| Moderate hypertension: SBP 160–179/ DBP 100–109 | 3 (1%) | ||
| 18 (4%) | |||
| Family History | 29 (6%) | ||
| Tuberculosis | 20 (69%) | ||
| Diabetes | 4 (14%) | ||
| High blood pressure | 2 (7%) | ||
| Alcoholism | 2 (7%) | ||
| Cancer | 1 (3%) | ||
| Other conditions | 52 (11%) | ||
| Pregnancy | 31 (60%) | ||
| Trauma- injury and violence | 6 (11%) | ||
| Epilepsy | 5 (10%) | ||
| Learning Difficulties | 5 (10%) | ||
| Failure to Thrive | 5 (10%) | ||
| 185 (38%) | |||
| Non-HIV infectious disease diagnosis | Tuberculosis | 114 (62%) | |
| Sexually Transmitted Infections | 40 (22%) | ||
| Scabies | 12 (6%) | ||
| Pneumonia | 9 (5%) | ||
| Herpes Simplex Virus | 5 (3%) | ||
| Meningitis | 5 (3%) | ||
| 135 (27%) | |||
| TB prophylaxis | 30 (22%) | ||
| Cotrimoxazole | 19 (14%) | ||
| STI treatment | 23 (17%) | ||
| Antibiotics | 44 (33%) | ||
| Steroids | 16 (12%) | ||
| Antivirals | 3 (2%) | ||
| 93 (19%)e | |||
| HIV-related | Disclosure counselling | 9 (7%) | |
| Adherence counselling | 11 (9%) | ||
| NCD-related | Alcohol counselling | 14 (11%) | |
| Mental health counselling | 13 (10%) | ||
| Healthy diet or weight counselling | 12 (9%) | ||
| Smoking counselling | 11 (9%) | ||
| Substance abuse counselling | 2 (2%) | ||
| Diabetes screening | 1 (1%) | ||
| Sexual and Reproductive Health | Family planning | 14 (11%) | |
| Basic antenatal counselling | 14 (11%) | ||
| Postnatal care & Infant feeding counselling | 10 (8%) | ||
| Pap smear & Breast examination | 6 (5%) | ||
| Safe sex counselling | 2 (2%) | ||
| Medical male circumcision | 2 (2%) | ||
| Other Health Promotion | Hygiene counselling | 4 (3%) | |
| Physiotherapy/Occupational Therapy | 2 (2%) | ||
aDenominator = 491, unless otherwise indicated in this column
bPercentages may not total 100 due to rounding
cIncludes asthma, Chronic Obstructive Pulmonary Disease, and other respiratory conditions
dSBP = Systolic Blood Pressure and DBP = Diastolic Blood Pressure
eTotal interventions > 93 as some individuals had more than one form of health promotion documented